| Particulars (Rupees in Crores.) | Mar-2025 | Dec-2024 | Sept-2024 | Jun-2024 | Mar-2024 |
|---|---|---|---|---|---|
Gross Sales | 2,909 | 2,762 | 2,831 | 2,815 | 2,695 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,909 | 2,762 | 2,831 | 2,815 | 2,695 |
Other Operating Income | 50 | 47 | 58 | 44 | 50 |
Other Income | -18 | 33 | -16 | 24 | 31 |
Total Income | 2,941 | 2,842 | 2,873 | 2,883 | 2,776 |
Total Expenditure | 2,019 | 1,895 | 1,950 | 1,955 | 1,862 |
PBIDT | 922 | 947 | 923 | 928 | 914 |
Interest | 56 | 57 | 64 | 75 | 80 |
PBDT | 866 | 890 | 859 | 853 | 834 |
Depreciation | 201 | 199 | 198 | 197 | 203 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 184 | 153 | 156 | 126 | 142 |
Deferred Tax | -17 | 35 | 52 | 73 | 40 |
Reported Profit After Tax | 498 | 503 | 453 | 457 | 449 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 498 | 503 | 453 | 457 | 449 |
Extra-ordinary Items | -17.36 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 515.36 | 503 | 453 | 457 | 449 |
EPS (Unit Curr.) | 14.71 | 14.88 | 13.37 | 13.51 | 13.27 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 520 | 0 | 0 | 0 |
Equity | 169.23 | 169.23 | 169.23 | 169.23 | 169.23 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 31.69 | 34.28 | 32.6 | 32.96 | 33.91 |
PBDTM(%) | 29.76 | 32.22 | 30.34 | 30.3 | 30.94 |
PATM(%) | 17.11 | 18.21 | 16 | 16.23 | 16.66 |
On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Bajaj Finance, Vedanta, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
